Literature DB >> 229975

Structure of the Abelson murine leukemia virus genome.

A Shields, S Goff, M Paskind, G Otto, D Baltimore.   

Abstract

Virions produced from cells transformed by A-MuLV contain a 30S, 5.6 kb RNA that can be translated in a cell-free system to form the characteristic A-MuLV protein. This RNA was mapped by heteroduplex methods using DNA probes from M-MuLV, the presumed parent of A-MuLV. The overall organization of the RNA was determined by using full-length M-MuLV reverse transcribed DNA and visualizing the heteroduplexes in the electron microscope. This showed that A-MuLV and M-MuLV have homologous sequences at both ends of their RNAs but that the central portion of the A-MuLV genome is not homologous to sequences in M-MuLV RNA. A precise measure of the lengths of the shared regions was obtained by using S1 nuclease to digest hybrids between 32P-labeled M-MuLV DNA and A-MuLV RNA; the resulting fragments were analyzed for their length by electrophoresis. The regions of homology were shown to be 1320 nucleotides long at the 5' end and 730 nucleotides long at the 3' end. Thus approximately 6200 nucleotides of the approximately 8300 in M-MuLV RNA were deleted when the A-MuLV genome was formed, but an insert of 3600 nucleotides, presumably derived from the normal murine genome, was inserted in place of the deleted region.

Entities:  

Mesh:

Substances:

Year:  1979        PMID: 229975     DOI: 10.1016/0092-8674(79)90208-3

Source DB:  PubMed          Journal:  Cell        ISSN: 0092-8674            Impact factor:   41.582


  35 in total

1.  Characterization of mouse cellular deoxyribonucleic acid homologous to Abelson murine leukemia virus-specific sequences.

Authors:  B Dale; B Ozanne
Journal:  Mol Cell Biol       Date:  1981-08       Impact factor: 4.272

2.  Moloney murine leukemia virus-induced myeloid tumors in adult BALB/c mice: requirement of c-myb activation but lack of v-abl involvement.

Authors:  G L Shen-Ong; L Wolff
Journal:  J Virol       Date:  1987-12       Impact factor: 5.103

3.  The complete coding sequence of arg defines the Abelson subfamily of cytoplasmic tyrosine kinases.

Authors:  G D Kruh; R Perego; T Miki; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1990-08       Impact factor: 11.205

4.  Generation of novel, biologically active Harvey sarcoma viruses via apparent illegitimate recombination.

Authors:  M P Goldfarb; R A Weinberg
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

5.  Some lymphoid cell lines transformed by Abelson murine leukemia virus lack a major 36,000-dalton tyrosine protein kinase substrate.

Authors:  B M Sefton; T Hunter; J A Cooper
Journal:  Mol Cell Biol       Date:  1983-01       Impact factor: 4.272

6.  Abelson murine leukemia virus: structural requirements for transforming gene function.

Authors:  A Srinivasan; C Y Dunn; Y Yuasa; S G Devare; E P Reddy; S A Aaronson
Journal:  Proc Natl Acad Sci U S A       Date:  1982-09       Impact factor: 11.205

7.  Only site-directed antibodies reactive with the highly conserved src-homologous region of the v-abl protein neutralize kinase activity.

Authors:  J B Konopka; R L Davis; S M Watanabe; A S Ponticelli; L Schiff-Maker; N Rosenberg; O N Witte
Journal:  J Virol       Date:  1984-07       Impact factor: 5.103

8.  Retrovirus-encoded transformation-specific polyproteins: expression coordinated with malignant phenotype in cells from different germ layers.

Authors:  A P Chen; M Essex; J A Shadduck; J Y Niederkorn; D Albert
Journal:  Proc Natl Acad Sci U S A       Date:  1981-06       Impact factor: 11.205

9.  A transformation-defective mutant of Abelson murine leukemia virus lacks protein kinase activity.

Authors:  O N Witte; S Goff; N Rosenberg; D Baltimore
Journal:  Proc Natl Acad Sci U S A       Date:  1980-08       Impact factor: 11.205

10.  Abelson murine leukemia virus transformation-defective mutants with impaired P120-associated protein kinase activity.

Authors:  F H Reynolds; W J Van de Ven; J R Stephenson
Journal:  J Virol       Date:  1980-11       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.